The instruction for medical use
of FOTILâ medicine
the Trade name
of Fotil®
the International unlicensed name
Is not present
the Dosage form
of the Drop eye, 5 ml
Structure
1 ml of solution contains
active agents: pilocarpine hydrochloride of 20 mg, Timololum maleate of 6.84 mg (ekv. to Timololum of 5 mg),
excipients: a benzalkoniya chloride, citric acid monohydrate, sodium citrate, a gipromelloza, water for injections.
Description
Transparent, colourless solution.
Pharmacotherapeutic group
Protivoglaukomny drugs and miotik. Pilocarpine in a combination with other drugs.
ATX S01EB51 code
the Pharmacological
Pharmacokinetics Pilocarpine properties quickly gets through a cornea. Concentration in watery moisture reaches the maximum in 30 min. Pilocarpine communicates many tissues of an eye. Elimination half-life makes 1.5 - 2.5 hours of environments of an eye. However hypotensive effect of drug remains within several hours.
Pilocarpine is removed in not changed view with intraocular liquid. Its combination with Timololum which reduces formation of watery moisture slows down pilocarpine clearance rate.
Pilocarpine is quickly hydrolyzed in blood plasma and a liver with formation of inactive forms. The period of its semi-removal is less than 0.5 hours.
Timololum quickly gets through a cornea into watery moisture of an anterior chamber of an eye.
About 80% of locally applied Timololum get into a system blood stream. The maximum concentration (Cmax) of Timololum in plasma is defined approximately in 1 hour after Timololum instillation. Elimination half-life makes 2-5 hours. Timololum is metabolized, mainly, in a liver under the influence of enzyme P450 2D6 cytochrome (CYP2D6). It is removed mainly through kidneys.
A pharmacodynamics
Eye drops of Fotil® contain two active agents. Pilocarpine is a parasympathomimetic which stimulates m - cholinergic receptors. After instillation in an eye, pilocarpine causes a miosis, a spasm of accommodation and reduces intraocular pressure. Decrease in intraocular pressure is caused by reduction of a tsiliarny muscle and muscle of an iris of the eye of an eye which leads to expansion of a corner of an anterior chamber of an eye and change of physical structure of trabecular network, facilitating outflow of watery moisture. This effect remains from 4 to 14 hour.
Timololum, being beta blocker, prevents linking of sympathomimetic neurotransmitters with the бета1st and beta2-adrenoceptors. It reduces intraocular pressure, reducing products of watery moisture. Targets of effect of Timololum are beta2-adrenergic receptors in a ciliary body. Considerable decrease in intraocular pressure is reached within 1 hour after a single dose of Fotila®. The maximum effect is usually observed within 3 hours.
Indications
Glaucoma or the increased intraocular pressure, at inefficiency of monotherapy and need of a combination of Timololum and pilocarpine:
- open and closed-angle angle glaucoma
- glaucoma at an aphakia
- secondary glaucoma
- in combination with in a different way treatment of glaucoma in case of
the significant increase in intraocular pressure
- increase in intraocular pressure after the ophthalmologic
operations Route of administration and a dose
the Usual dosage - on 1 drop in the affected eye 2 times a day. Some patients have a steady decrease in the intraocular pressure caused by the drug Fotil®, is reached only in several weeks therefore assessment of therapy has to include measurement of intraocular pressure approximately in 4 weeks after an initiation of treatment.
If the intraocular pressure of the patient remains to Fotil® raised at treatment by eye drops, it is recommended to continue treatment by eye drops of Fotil® forte, on 1 drop 2 times a day. Further increase in a dose usually does not reduce intraocular pressure any more. If intraocular pressure does not keep at the satisfactory level at use of the specified drug dose, the doctor should revise the scheme of therapy.
When occlusion of a nasal duct or closing a century for 2 minutes is used, system absorption of medicine decreases. As a result risk of development of system side reactions decreases, and the local effect amplifies.
Side effects
of Timololum a maleate
At topical administration ophthalmologic beta blockers are absorbed in a system blood stream that can lead ment of undesirable side effects, similar to those that are observed at their system use. Risk of development of system side reactions at topical ophthalmologic administration is lower, than at system use. Following side effects are characteristic of all group of beta blockers for ophthalmologic use.
Immune system: system allergic reactions, including a Quincke's edema, the urticaria localized and generalizoanny rash, an itching, anaphylactic reactions.
Metabolic disturbances: hypoglycemia.
Psychiatric disturbances: insomnia, depression, nightmares, memory loss.
Disorders of nervous system: faint, cerebrovascular complications, cerebral ischemia, strengthening of manifestation of signs and symptoms of a myasthenia (asthenic bulbar paralysis), dizziness, parasthesias, headache.
Eye disturbances: signs and symptoms of irritation of an eye (burning, pricking, an itching, dacryagogue, reddening), blepharitis, a keratitis, decrease in visual acuity and amotio of a choroid of an eye after filtration operation (see the section Special Instructions), decrease in sensitivity of a cornea, dryness of an eye, a cornea erosion, a ptosis, a diplopia.
Warm disturbances: bradycardia, a stethalgia, a cardiopalmus, swell, arrhythmias, stagnant heart failure, atrioventricular block, cardiac arrest, heart failure.
Vascular disorders: hypotonia, Reynaud's syndrome, cold hands and legs.
Respiratory disturbances: a bronchospasm, (mainly at patients with a bronkhospastichesky disease in the anamnesis), short wind, cough.
Gastrointestinal disorders: a food faddism, nausea, dyspepsia, diarrhea, dryness in a mouth, an abdominal pain, vomiting.
Skin and hypodermic cellulose: alopecia, psoriazopodobny rash, exacerbation of psoriasis, skin rash.
Musculoskeletal system: myalgia.
Reproductive system: sexual dysfunctions, decrease in a libido.
General disturbances: asthenia/weakness.
The following side effects, in addition to above-mentioned, were described at use of ophthalmologic beta-blockers which can arise also during a usage time of eye drops of Fotil®:
From eyes:
Infrequently (≥ 1/1,000 to & lt, 1/100): decrease in sensitivity of a cornea, superficial dot keratitis.
Seldom (≥ 1/10,000 to & lt, 1/1,000): the syndrome of a dry eye, blefarokonjyunktivit, disorders of vision, doubling in eyes, a ptosis.
From a warm system
Infrequently (≥ 1/1,000 to & lt, 1/100): bradycardia.
Seldom (≥ 1/10,000 to & lt, 1/1,000): heart failure, arrhythmias.
From the vascular system
Seldom (≥ 1/10,000 to & lt, 1/1,000): hypotension, decrease in a peripheral and cerebral blood-groove.
Disorders of nervous system
Often (≥ 1/100 to & lt, 1/10): headache.
Seldom (≥ 1/10,000 to & lt, 1/1,000): dizziness.
Respiratory, thoracic and mediastinal disturbances
Infrequently (≥ 1/1,000 to & lt, 1/100): dispnoe.
Seldom (≥ 1/10,000 to & lt, 1/1,000): a bronchospasm (mainly at patients with bronkhospastichesky diseases in the anamnesis, such as asthma or cordial insufficiency), congestion of a nose.
Psychiatric disturbances:
Infrequently (≥ 1/1,000 to & lt, 1/100): depression.
Seldom (≥ 1/10,000 to & lt, 1/1,000): hallucinations, alarm, nightmares, confusion of consciousness.
Skin and hypodermic cellulose:
Seldom (≥ 1/10,000 to & lt, 1/1,000): reactions of hypersensitivity: rash, urticaria, alopecia.
The general disturbances
Infrequently (≥ 1/1,000 to & lt, 1/100): weakness.
Seldom (≥ 1/10,000 to & lt, 1/1,000): asthenia.
Pilocarpine a hydrochloride
from eyes:
Often (≥1/100 to & lt, 1/10): passing pricking or burning, decrease in visual acuity, increase in dacryagogue, a spasm of a tsiliarny muscle, stagnation in retina vessels, conjunctiva hyperaemia, eye pain, an itching, irritation, a headache in temporal and supraorbital areas, decrease in visual acuity at bad lighting (in connection with development of a miosis, especially at patients with a cataract), shortsightedness or disturbance of accommodation.
Seldom (≥1/10,000 to & lt, 1/1,000): amotio of a retina, a vitreous hemorrhage, rigidity of an iris, a cyst of an iris of the eye, vasodilatation of an iris of the eye, reduction a century, narrowing of an anterior chamber, reversible tarnishing of a crystalline lens (at prolonged use of pilocarpine).
From outside warmly - the vascular system:
Not often (≥1/1,000 to & lt, 1/100): lowering of arterial pressure.
Digestive tract:
Not often (≥1/1,000 to & lt, 1/100): nausea.
Seldom (≥1/10,000 to & lt, 1/1,000): vomiting, the increased salivation, diarrhea.
General disturbances:
Seldom (≥1/10,000 to & lt, 1/1,000): the increased sweating.
In case of the side reactions including which are not specified in this instruction it is necessary to see
a doctor Protivopokazaniya
- a front uveitis
- sinus bradycardia
- a sick sinus syndrome
- sinoauricular block of heart
- the atrioventricular block of the II-III degree which is not controlled by a pacemaker
- the profound heart failure
- cardiogenic shock
- reactive respiratory diseases, including bronchial asthma or bronchial asthma in the anamnesis
- a serious chronic obstructive illness of lungs
- children's age up to 18 years (due to the lack of data on efficiency and safety of drug at children and teenagers up to 18 years)
- hypersensitivity to active agents (maleate/pilocarpine Timololum a hydrochloride) or any of drug components
- a state directly after ophthalmologic operations, etc. diseases of eyes in which it is necessary to avoid a miosis
- cholinergic connections (pilocarpine) are contraindicated at an acute inflammation of an iris of the eye.
Medicinal interactions
No specific researches on development of reactions of interaction of Timololum and pilocarpine with other medicines were conducted. The drugs breaking deposition of catecholamines (reserpine) contribute to the development of arterial hypotension (including orthostatic), bradycardia and dizziness.
Sharing of Timololum with the eye drops containing adrenaline (epinephrine) can cause a mydriasis (mydriasis).
Simultaneous use of beta blockers, blockers of slow calcium channels of systemic action, antiarrhytmic medicines (including Amiodaronum), glycosides of a foxglove, parasympathomimetics and a guanetidin leads to strengthening of their pharmacological effect, and increases risk of development of disturbances of warm conductivity and arterial hypotension.
It was reported about increase in risk of development of system side reactions (decrease in heart rate, a depression) at simultaneous use of Timololum with CYP2D6 inhibitors (for example, quinidine, fluoxetine, a paroksetin) as CYP2D6 inhibitors can increase concentration of Timololum in plasma.
The special
instructions Use of Other Eye Drops it has to be stopped before therapy is begun with the drug Fotilâ: the previous antiglaukomny means has to be cancelled, and therapy by eye drops of Fotilâ has to be begun next day.
The assessment of efficiency of action should be carried out in 4 weeks after an initiation of treatment at regular control of intraocular pressure.
Further treatment also should be carried out under regular control of intraocular pressure.
As well as other ophthalmologic drugs for topical administration, Timololum a maleate and pilocarpine a hydrochloride are absorbed systemically. Beta-blockers for topical administration, such as Timololum, can cause development of undesirable side reactions from cardiovascular, pulmonary and other systems, as well as at use of system beta blockers. Frequency of development of system side reactions after use of eye drops with beta-blockers is lower, than at their system use:
Heart diseases: At patients with cardiovascular diseases (for example, coronary heart disease, Printsmetal's stenocardia, heart failure) and arterial hypotension therapy by beta-blockers has to be critically estimated, and treatment by other medicines with other active agents has to be considered. Stimulation of sympathetic nervous system can be an essential factor for maintenance of blood circulation at patients with reduced sokratitelny ability of a myocardium, and its inhibition beta-blockers can cause a decompensation of heart failure. Patients with the first extent of heart block should appoint beta-blockers with care because of negative impact on time of carrying out excitement. Patients with cardiovascular diseases need to be observed on existence of deterioration in symptoms of these diseases and side reactions.
Vascular diseases: Patients with peripheral circulator disturbances / diseases (severe form of a Raynaud's disease or Reynaud's syndrome) should be treated with care.
Disturbance of respiratory functions: It was reported about development of respiratory reactions, including death owing to a bronchospasm at patients with bronchial asthma, at use of the eye drops containing beta-blockers. Fotilâ it is necessary to apply with care at patients with easy and average degree of a chronic obstructive pulmonary disease and, only when the potential advantage exceeds risk.
Hypoglycemia/diabetes: Beta-blockers should be applied with care at the patients subject ment of a spontaneous hypoglycemia or in patients with unstable diabetes as beta-blockers can mask signs and symptoms of a sharp hypoglycemia.
Beta-blockers can mask hyperthyroidism symptoms.
Cornea diseases: Ophthalmologic beta-blockers can cause xerophthalmus. Patients with diseases of a cornea should be treated with care.
Other beta-blockers: Influence on intraocular pressure or the known system effect of beta-blockers can be exponentiated when the patient already applies system beta-blockers. The response to intake of these medicines needs to be observed carefully. Use of two beta blockers for topical administration is not recommended (see the section Interaction with Other Medicines).
Anaphylactic reactions: The patients accepting local beta-blockers at which in the anamnesis allergic or heavy anaphylactic reactions to different allergens are noted can react more reactively to repeated administration of allergens and not answer a usual dose of adrenaline at treatment of anaphylactic reaction.
Amotio of a choroid of an eye: Cases of amotio of a choroid of an eye at use of the medicines interfering formation of intraocular liquid are described (for example, Timololum, acetazoleamide) after the filtering operations.
Surgical anesthesia: Ophthalmologic beta-blockers can block systemic action of beta-agonists, for example adrenaline. The anesthesiologist has to be informed if the patient receives Fotilâ.
A way of reduction of system absorption, see in the section Route of Administration and Doses.
Eye drops of Fotilâ contain in quality of preservative a benzalkoniya chloride, and they are not recommended to be used when carrying contact lenses. Before use of drug it is necessary to remove contact lenses and again to establish them not earlier than in 15 minutes.
Pregnancy and the period of a lactation
Are not present sufficient data on use of Timololum or pilocarpine for pregnant women. Eye drops of Fotilâ should not be applied during pregnancy, except for cases when it is really necessary. A way of reduction of system absorption, see in the section Route of Administration and Doses.
Epidemiological researches did not reveal influence of beta-blockers on development of congenital malformations in a fruit (teratogenic effect), however showed a pre-natal growth inhibition at oral administration. Signs and symptoms of beta blockade (bradycardia, hypotension, a respiratory distress syndrome, a hypoglycemia) were observed at newborns if beta-blockers applied before childbirth. If Fotilâ was applied just before childbirth, then newborns have to be under careful observation within several days after the birth.
Beta-blockers are allocated with breast milk. However it is improbable that Timololum in enough will be present at breast milk to cause development of clinical symptoms of beta blockade in newborns.
A way of reduction of system absorption, see in the section Route of Administration and Doses.
Features of influence of medicine on ability to run the vehicle or potentially dangerous mechanisms
Eye drops of Fotilâ can affect ability to drive the car, and to operate the difficult equipment. The miosis usually causes difficulty of adaptation to darkness. The patient should refrain from driving in night-time. Timololum can lower arterial blood pressure that can result in passing fatigue and dizziness at some patients. It should be explained to the patient, at treatment initiation. Short-term misting of sight can be observed after instillation of eye drops of Fotil®.
If the specified side effects from nervous or eye systems are noted, the patient should refuse driving of the car or work with difficult mechanisms, machines or any other difficult equipment demanding concentration of attention and speed of psychomotor reactions.
The overdose
As, drug is quickly soaked up through mucous eyes and a nose, several drops of Fotil® can cause arrhythmias, tranzitorny delay of pulse, falling of arterial blood pressure, a bronchospasm or heart failure.
In case of overdose it is necessary to see a doctor immediately.
Treatment, mainly, symptomatic. Atropine can be used as pilocarpine antidote. Izoprenalin it is possible to enter intravenously for elimination of the profound bradycardia or a bronchospasm, Dobutaminum for treatment of arterial hypotension.
A form of release and packing
On 5 ml in the polyethylene bottles droppers corked by plastic traffic jams with the screwing covers. On 1 bottle with the instruction for use in the state and Russian languages place in a box cardboard.
To Store storage conditions at a temperature from + 2 to + 8 °C.
The open bottle is stored at the room temperature not over 25 ºС
to Store out of children's reach!
A period of storage
3 years
After opening of a bottle – 1 month.
Not to use after the expiration date specified on packing.
Prescription status
According to the prescription
JSC Sangteng Producer, Niittyukhaankatu 20, 33720 Tampere, Finland
the Owner of the registration certificate
of JSC Sangteng, Finland
the Address of the organization accepting in the territory of the Republic of Kazakhstan claims from consumers on quality of products (goods)
Representative office of JSC Canten in
Kazakhstan Almaty, Zheltoksan St., 129/65 quarter
56 Phone number –
250-39-17 Fax number - 250-39-17
E-mail address:
atlana_kz@rambler.ru
of FOTILâ medicine
the Trade name
of Fotil®
the International unlicensed name
Is not present
the Dosage form
of the Drop eye, 5 ml
Structure
1 ml of solution contains
active agents: pilocarpine hydrochloride of 20 mg, Timololum maleate of 6.84 mg (ekv. to Timololum of 5 mg),
excipients: a benzalkoniya chloride, citric acid monohydrate, sodium citrate, a gipromelloza, water for injections.
Description
Transparent, colourless solution.
Pharmacotherapeutic group
Protivoglaukomny drugs and miotik. Pilocarpine in a combination with other drugs.
ATX S01EB51 code
the Pharmacological
Pharmacokinetics Pilocarpine properties quickly gets through a cornea. Concentration in watery moisture reaches the maximum in 30 min. Pilocarpine communicates many tissues of an eye. Elimination half-life makes 1.5 - 2.5 hours of environments of an eye. However hypotensive effect of drug remains within several hours.
Pilocarpine is removed in not changed view with intraocular liquid. Its combination with Timololum which reduces formation of watery moisture slows down pilocarpine clearance rate.
Pilocarpine is quickly hydrolyzed in blood plasma and a liver with formation of inactive forms. The period of its semi-removal is less than 0.5 hours.
Timololum quickly gets through a cornea into watery moisture of an anterior chamber of an eye.
About 80% of locally applied Timololum get into a system blood stream. The maximum concentration (Cmax) of Timololum in plasma is defined approximately in 1 hour after Timololum instillation. Elimination half-life makes 2-5 hours. Timololum is metabolized, mainly, in a liver under the influence of enzyme P450 2D6 cytochrome (CYP2D6). It is removed mainly through kidneys.
A pharmacodynamics
Eye drops of Fotil® contain two active agents. Pilocarpine is a parasympathomimetic which stimulates m - cholinergic receptors. After instillation in an eye, pilocarpine causes a miosis, a spasm of accommodation and reduces intraocular pressure. Decrease in intraocular pressure is caused by reduction of a tsiliarny muscle and muscle of an iris of the eye of an eye which leads to expansion of a corner of an anterior chamber of an eye and change of physical structure of trabecular network, facilitating outflow of watery moisture. This effect remains from 4 to 14 hour.
Timololum, being beta blocker, prevents linking of sympathomimetic neurotransmitters with the бета1st and beta2-adrenoceptors. It reduces intraocular pressure, reducing products of watery moisture. Targets of effect of Timololum are beta2-adrenergic receptors in a ciliary body. Considerable decrease in intraocular pressure is reached within 1 hour after a single dose of Fotila®. The maximum effect is usually observed within 3 hours.
Indications
Glaucoma or the increased intraocular pressure, at inefficiency of monotherapy and need of a combination of Timololum and pilocarpine:
- open and closed-angle angle glaucoma
- glaucoma at an aphakia
- secondary glaucoma
- in combination with in a different way treatment of glaucoma in case of
the significant increase in intraocular pressure
- increase in intraocular pressure after the ophthalmologic
operations Route of administration and a dose
the Usual dosage - on 1 drop in the affected eye 2 times a day. Some patients have a steady decrease in the intraocular pressure caused by the drug Fotil®, is reached only in several weeks therefore assessment of therapy has to include measurement of intraocular pressure approximately in 4 weeks after an initiation of treatment.
If the intraocular pressure of the patient remains to Fotil® raised at treatment by eye drops, it is recommended to continue treatment by eye drops of Fotil® forte, on 1 drop 2 times a day. Further increase in a dose usually does not reduce intraocular pressure any more. If intraocular pressure does not keep at the satisfactory level at use of the specified drug dose, the doctor should revise the scheme of therapy.
When occlusion of a nasal duct or closing a century for 2 minutes is used, system absorption of medicine decreases. As a result risk of development of system side reactions decreases, and the local effect amplifies.
Side effects
of Timololum a maleate
At topical administration ophthalmologic beta blockers are absorbed in a system blood stream that can lead ment of undesirable side effects, similar to those that are observed at their system use. Risk of development of system side reactions at topical ophthalmologic administration is lower, than at system use. Following side effects are characteristic of all group of beta blockers for ophthalmologic use.
Immune system: system allergic reactions, including a Quincke's edema, the urticaria localized and generalizoanny rash, an itching, anaphylactic reactions.
Metabolic disturbances: hypoglycemia.
Psychiatric disturbances: insomnia, depression, nightmares, memory loss.
Disorders of nervous system: faint, cerebrovascular complications, cerebral ischemia, strengthening of manifestation of signs and symptoms of a myasthenia (asthenic bulbar paralysis), dizziness, parasthesias, headache.
Eye disturbances: signs and symptoms of irritation of an eye (burning, pricking, an itching, dacryagogue, reddening), blepharitis, a keratitis, decrease in visual acuity and amotio of a choroid of an eye after filtration operation (see the section Special Instructions), decrease in sensitivity of a cornea, dryness of an eye, a cornea erosion, a ptosis, a diplopia.
Warm disturbances: bradycardia, a stethalgia, a cardiopalmus, swell, arrhythmias, stagnant heart failure, atrioventricular block, cardiac arrest, heart failure.
Vascular disorders: hypotonia, Reynaud's syndrome, cold hands and legs.
Respiratory disturbances: a bronchospasm, (mainly at patients with a bronkhospastichesky disease in the anamnesis), short wind, cough.
Gastrointestinal disorders: a food faddism, nausea, dyspepsia, diarrhea, dryness in a mouth, an abdominal pain, vomiting.
Skin and hypodermic cellulose: alopecia, psoriazopodobny rash, exacerbation of psoriasis, skin rash.
Musculoskeletal system: myalgia.
Reproductive system: sexual dysfunctions, decrease in a libido.
General disturbances: asthenia/weakness.
The following side effects, in addition to above-mentioned, were described at use of ophthalmologic beta-blockers which can arise also during a usage time of eye drops of Fotil®:
From eyes:
Infrequently (≥ 1/1,000 to & lt, 1/100): decrease in sensitivity of a cornea, superficial dot keratitis.
Seldom (≥ 1/10,000 to & lt, 1/1,000): the syndrome of a dry eye, blefarokonjyunktivit, disorders of vision, doubling in eyes, a ptosis.
From a warm system
Infrequently (≥ 1/1,000 to & lt, 1/100): bradycardia.
Seldom (≥ 1/10,000 to & lt, 1/1,000): heart failure, arrhythmias.
From the vascular system
Seldom (≥ 1/10,000 to & lt, 1/1,000): hypotension, decrease in a peripheral and cerebral blood-groove.
Disorders of nervous system
Often (≥ 1/100 to & lt, 1/10): headache.
Seldom (≥ 1/10,000 to & lt, 1/1,000): dizziness.
Respiratory, thoracic and mediastinal disturbances
Infrequently (≥ 1/1,000 to & lt, 1/100): dispnoe.
Seldom (≥ 1/10,000 to & lt, 1/1,000): a bronchospasm (mainly at patients with bronkhospastichesky diseases in the anamnesis, such as asthma or cordial insufficiency), congestion of a nose.
Psychiatric disturbances:
Infrequently (≥ 1/1,000 to & lt, 1/100): depression.
Seldom (≥ 1/10,000 to & lt, 1/1,000): hallucinations, alarm, nightmares, confusion of consciousness.
Skin and hypodermic cellulose:
Seldom (≥ 1/10,000 to & lt, 1/1,000): reactions of hypersensitivity: rash, urticaria, alopecia.
The general disturbances
Infrequently (≥ 1/1,000 to & lt, 1/100): weakness.
Seldom (≥ 1/10,000 to & lt, 1/1,000): asthenia.
Pilocarpine a hydrochloride
from eyes:
Often (≥1/100 to & lt, 1/10): passing pricking or burning, decrease in visual acuity, increase in dacryagogue, a spasm of a tsiliarny muscle, stagnation in retina vessels, conjunctiva hyperaemia, eye pain, an itching, irritation, a headache in temporal and supraorbital areas, decrease in visual acuity at bad lighting (in connection with development of a miosis, especially at patients with a cataract), shortsightedness or disturbance of accommodation.
Seldom (≥1/10,000 to & lt, 1/1,000): amotio of a retina, a vitreous hemorrhage, rigidity of an iris, a cyst of an iris of the eye, vasodilatation of an iris of the eye, reduction a century, narrowing of an anterior chamber, reversible tarnishing of a crystalline lens (at prolonged use of pilocarpine).
From outside warmly - the vascular system:
Not often (≥1/1,000 to & lt, 1/100): lowering of arterial pressure.
Digestive tract:
Not often (≥1/1,000 to & lt, 1/100): nausea.
Seldom (≥1/10,000 to & lt, 1/1,000): vomiting, the increased salivation, diarrhea.
General disturbances:
Seldom (≥1/10,000 to & lt, 1/1,000): the increased sweating.
In case of the side reactions including which are not specified in this instruction it is necessary to see
a doctor Protivopokazaniya
- a front uveitis
- sinus bradycardia
- a sick sinus syndrome
- sinoauricular block of heart
- the atrioventricular block of the II-III degree which is not controlled by a pacemaker
- the profound heart failure
- cardiogenic shock
- reactive respiratory diseases, including bronchial asthma or bronchial asthma in the anamnesis
- a serious chronic obstructive illness of lungs
- children's age up to 18 years (due to the lack of data on efficiency and safety of drug at children and teenagers up to 18 years)
- hypersensitivity to active agents (maleate/pilocarpine Timololum a hydrochloride) or any of drug components
- a state directly after ophthalmologic operations, etc. diseases of eyes in which it is necessary to avoid a miosis
- cholinergic connections (pilocarpine) are contraindicated at an acute inflammation of an iris of the eye.
Medicinal interactions
No specific researches on development of reactions of interaction of Timololum and pilocarpine with other medicines were conducted. The drugs breaking deposition of catecholamines (reserpine) contribute to the development of arterial hypotension (including orthostatic), bradycardia and dizziness.
Sharing of Timololum with the eye drops containing adrenaline (epinephrine) can cause a mydriasis (mydriasis).
Simultaneous use of beta blockers, blockers of slow calcium channels of systemic action, antiarrhytmic medicines (including Amiodaronum), glycosides of a foxglove, parasympathomimetics and a guanetidin leads to strengthening of their pharmacological effect, and increases risk of development of disturbances of warm conductivity and arterial hypotension.
It was reported about increase in risk of development of system side reactions (decrease in heart rate, a depression) at simultaneous use of Timololum with CYP2D6 inhibitors (for example, quinidine, fluoxetine, a paroksetin) as CYP2D6 inhibitors can increase concentration of Timololum in plasma.
The special
instructions Use of Other Eye Drops it has to be stopped before therapy is begun with the drug Fotilâ: the previous antiglaukomny means has to be cancelled, and therapy by eye drops of Fotilâ has to be begun next day.
The assessment of efficiency of action should be carried out in 4 weeks after an initiation of treatment at regular control of intraocular pressure.
Further treatment also should be carried out under regular control of intraocular pressure.
As well as other ophthalmologic drugs for topical administration, Timololum a maleate and pilocarpine a hydrochloride are absorbed systemically. Beta-blockers for topical administration, such as Timololum, can cause development of undesirable side reactions from cardiovascular, pulmonary and other systems, as well as at use of system beta blockers. Frequency of development of system side reactions after use of eye drops with beta-blockers is lower, than at their system use:
Heart diseases: At patients with cardiovascular diseases (for example, coronary heart disease, Printsmetal's stenocardia, heart failure) and arterial hypotension therapy by beta-blockers has to be critically estimated, and treatment by other medicines with other active agents has to be considered. Stimulation of sympathetic nervous system can be an essential factor for maintenance of blood circulation at patients with reduced sokratitelny ability of a myocardium, and its inhibition beta-blockers can cause a decompensation of heart failure. Patients with the first extent of heart block should appoint beta-blockers with care because of negative impact on time of carrying out excitement. Patients with cardiovascular diseases need to be observed on existence of deterioration in symptoms of these diseases and side reactions.
Vascular diseases: Patients with peripheral circulator disturbances / diseases (severe form of a Raynaud's disease or Reynaud's syndrome) should be treated with care.
Disturbance of respiratory functions: It was reported about development of respiratory reactions, including death owing to a bronchospasm at patients with bronchial asthma, at use of the eye drops containing beta-blockers. Fotilâ it is necessary to apply with care at patients with easy and average degree of a chronic obstructive pulmonary disease and, only when the potential advantage exceeds risk.
Hypoglycemia/diabetes: Beta-blockers should be applied with care at the patients subject ment of a spontaneous hypoglycemia or in patients with unstable diabetes as beta-blockers can mask signs and symptoms of a sharp hypoglycemia.
Beta-blockers can mask hyperthyroidism symptoms.
Cornea diseases: Ophthalmologic beta-blockers can cause xerophthalmus. Patients with diseases of a cornea should be treated with care.
Other beta-blockers: Influence on intraocular pressure or the known system effect of beta-blockers can be exponentiated when the patient already applies system beta-blockers. The response to intake of these medicines needs to be observed carefully. Use of two beta blockers for topical administration is not recommended (see the section Interaction with Other Medicines).
Anaphylactic reactions: The patients accepting local beta-blockers at which in the anamnesis allergic or heavy anaphylactic reactions to different allergens are noted can react more reactively to repeated administration of allergens and not answer a usual dose of adrenaline at treatment of anaphylactic reaction.
Amotio of a choroid of an eye: Cases of amotio of a choroid of an eye at use of the medicines interfering formation of intraocular liquid are described (for example, Timololum, acetazoleamide) after the filtering operations.
Surgical anesthesia: Ophthalmologic beta-blockers can block systemic action of beta-agonists, for example adrenaline. The anesthesiologist has to be informed if the patient receives Fotilâ.
A way of reduction of system absorption, see in the section Route of Administration and Doses.
Eye drops of Fotilâ contain in quality of preservative a benzalkoniya chloride, and they are not recommended to be used when carrying contact lenses. Before use of drug it is necessary to remove contact lenses and again to establish them not earlier than in 15 minutes.
Pregnancy and the period of a lactation
Are not present sufficient data on use of Timololum or pilocarpine for pregnant women. Eye drops of Fotilâ should not be applied during pregnancy, except for cases when it is really necessary. A way of reduction of system absorption, see in the section Route of Administration and Doses.
Epidemiological researches did not reveal influence of beta-blockers on development of congenital malformations in a fruit (teratogenic effect), however showed a pre-natal growth inhibition at oral administration. Signs and symptoms of beta blockade (bradycardia, hypotension, a respiratory distress syndrome, a hypoglycemia) were observed at newborns if beta-blockers applied before childbirth. If Fotilâ was applied just before childbirth, then newborns have to be under careful observation within several days after the birth.
Beta-blockers are allocated with breast milk. However it is improbable that Timololum in enough will be present at breast milk to cause development of clinical symptoms of beta blockade in newborns.
A way of reduction of system absorption, see in the section Route of Administration and Doses.
Features of influence of medicine on ability to run the vehicle or potentially dangerous mechanisms
Eye drops of Fotilâ can affect ability to drive the car, and to operate the difficult equipment. The miosis usually causes difficulty of adaptation to darkness. The patient should refrain from driving in night-time. Timololum can lower arterial blood pressure that can result in passing fatigue and dizziness at some patients. It should be explained to the patient, at treatment initiation. Short-term misting of sight can be observed after instillation of eye drops of Fotil®.
If the specified side effects from nervous or eye systems are noted, the patient should refuse driving of the car or work with difficult mechanisms, machines or any other difficult equipment demanding concentration of attention and speed of psychomotor reactions.
The overdose
As, drug is quickly soaked up through mucous eyes and a nose, several drops of Fotil® can cause arrhythmias, tranzitorny delay of pulse, falling of arterial blood pressure, a bronchospasm or heart failure.
In case of overdose it is necessary to see a doctor immediately.
Treatment, mainly, symptomatic. Atropine can be used as pilocarpine antidote. Izoprenalin it is possible to enter intravenously for elimination of the profound bradycardia or a bronchospasm, Dobutaminum for treatment of arterial hypotension.
A form of release and packing
On 5 ml in the polyethylene bottles droppers corked by plastic traffic jams with the screwing covers. On 1 bottle with the instruction for use in the state and Russian languages place in a box cardboard.
To Store storage conditions at a temperature from + 2 to + 8 °C.
The open bottle is stored at the room temperature not over 25 ºС
to Store out of children's reach!
A period of storage
3 years
After opening of a bottle – 1 month.
Not to use after the expiration date specified on packing.
Prescription status
According to the prescription
JSC Sangteng Producer, Niittyukhaankatu 20, 33720 Tampere, Finland
the Owner of the registration certificate
of JSC Sangteng, Finland
the Address of the organization accepting in the territory of the Republic of Kazakhstan claims from consumers on quality of products (goods)
Representative office of JSC Canten in
Kazakhstan Almaty, Zheltoksan St., 129/65 quarter
56 Phone number –
250-39-17 Fax number - 250-39-17
E-mail address:
atlana_kz@rambler.ru
Related Products
